Imatinib
- TRADE NAMES: Gleevec (Novartis); Glivec
- INDICATIONS: Chronic myeloid leukemia
- CLASS: Antineoplastic, Biologic, CYP3A4 inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 18 hours
Acetaminophen, Amlodipine, Anisindione, Anticoagulants, Aprepitant, Atorvastatin, Barbiturates, Benzodiazepines, Butabarbital, Carbamazepine, Chlordiazepoxide, Clarithromycin, Clonazepam, Clorazepate, Corticosteroids, Cyclosporine, Dexamethasone, Diazepam, Dicumarol, Efavirenz, Erythromycin, Ethotoin, Felodipine, Flurazepam, Fluvastatin, Fosphenytoin, Isradipine, Itraconazole, Ketoconazole, Lorazepam, Lovastatin, Mephenytoin, Mephobarbital, Midazolam, Mifepristone, Neratinib, Nicardipine, Nifedipine, Nimodipine, Nisoldipine, Olaparib, Oxazepam, Oxcarbazepine, Pentobarbital, Phenobarbital, Phenytoin, Pimozide, Pravastatin, Primidone, Quazepam, Rifampin, Rifapentine, Safinamide, Secobarbital, Simvastatin, St John's Wort, Temazepam, Voriconazole, Warfarin
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of imatinib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 06/19/2019
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
